Form 8 (OPD)

Renalytix PLC

14 March 2024

 

Renalytix plc

("Renalytix plc" or the "Company")

The following correction has been made to the "FORM 8 (OPD)", which was released on 8 March 2024 at 12:14am UK time under RNS no. 1928G.  

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1.            KEY INFORMATION

(a) Full name of discloser:	Renalytix PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree	Renalytix PLC
(d) Is the discloser the offeror or the offeree?	OFFEREE
(e) Date position held:        The latest practicable date prior to the disclosure	7 March 2024
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?        If it is a cash offer or possible cash offer, state "N/A"	N/A

2.            POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)          Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	0.25p ordinary shares
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil	0	Nil	0
(2) Cash-settled derivatives:	Nil	0	Nil	0
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	0	Nil	0
TOTAL:	Nil	0	Nil	0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)          Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	NONE
Details, including nature of the rights concerned and relevant percentages:	NONE

3.            POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

a)    Interests in ordinary shares 0.25 pence each in which the Directors of Renalytix PLC are interested (and their close relatives and related trusts): Renalytix PLC Director Position Number of 0.25p ordinary shares Percentage of total issued share capital of Renalytix PLC Christopher Mills* Non-Executive Chairman 10,072,500** 10.07% James McCullough Chief Executive Officer 2,746,386 2.74% Fergus Fleming Chief Technology Officer 569,481 0.56% *: Christopher Mills is the Chief Executive Officer and Chief Investment Officer of Harwood Capital Management Limited ("HCM"). HCM (via its wholly owned subsidiaries) is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and Oryx International Growth Fund Limited. Christopher Mills' interest is held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP. **: this number does not include 72,541 ordinary shares of 0.25p each held by certain Harwood discretionary clients. b)    Options held by the Directors of Renalytix PLC, their close relatives and related trusts: Renalytix PLC Director Position Share Scheme Grant Date Expiry Date Option Price (£) Number of Ordinary Shares (under option) Christopher Mills Non-Executive Chairman CSOP 17/11/2023 17/11/2033 £0.245 95,000 Daniel Levangie Non-Executive Director CSOP 17/11/2023 17/11/2033 £0.245 95,000 CSOP 27/01/2022 27/01/2032 £4.95 40,000 Catherine Coste Non-Executive Director CSOP 17/11/2023 17/11/2033 £0.245 95,000 CSOP 06/07/2023 06/07/2033 £1.025 190,000 James McCullough Chief Executive Officer CSOP 06/07/2023 06/07/2033 £1.025 875,017 Fergus Fleming Chief Technology Officer CSOP 06/07/2023 06/07/2033 £1.025 352,902

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4.            OTHER INFORMATION

(a)          Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b)          Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	8 March 2024
Contact name:	O. James Sterling
Telephone number:	[phone]

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on [phone].

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

For further information, please contact:

Renalytix plc James McCullough, CEO	www.renalytix.com Via Walbrook PR
Stifel (Nomad and Joint Broker to Renalytix) Nicholas Moore / Nick Harland / Samira Essebiyea	Tel: [phone]
Investec Bank plc (Joint Broker) Gary Clarence / Shalin Bhamra	Tel: [phone]
Walbrook PR Limited Paul McManus / Alice Woodings / Charlotte Edgar	Tel: [phone] or [e-mail] Mob: [phone]
CapComm Partners Peter DeNardo	Tel: [phone] or [e-mail]

 

END